Skip to content
Home/Companies/Biotech/Ionlace

Ionlace

Biotech·Sweden·Active·3yr hold
Entry
2023
Hold
3yr
Status
Active

Who owns Ionlace?

Ionlace is a Swedish Biotech company, currently owned by Heartcore Capital since 2023.

Hand-verified · updated 2026-08-18

Open JSON · CC-BY
Heartcore Capital
Investor
Heartcore Capital
Heartcore Capital Fund IV · 2021 · VC

Key facts

HQSweden
SectorBiotech
StatusActive

More from Heartcore Capital Fund IV

Other portfolio companies in the same fund.

Axana
Active
HealthTechUK· 2024
Byway
Active
HospitalityUK· 2024
Cula Technologies
Active
ClimateTechGermany· 2024
Skynopy
Active
Aerospace & DefenceFrance· 2024
Sunbeam
Active
Data & AnalyticsUK· 2024
Voyfai
Active
LogisticsGermany· 2024

More PE-backed in Biotech

Comparable biotech deals from other GPs.

Abbisko Healthcare
Active
The Carlyle GroupChina
Adagene
Active
General AtlanticChina
Advanced Cell Diagnostics
Active
Summit PartnersUS
Akero Therapeutics
Akero Therapeutics
Active
General AtlanticUS
Aldevron
Aldevron
Active
TA AssociatesUS
Alloy Therapeutics
Alloy Therapeutics
Active
Mubadala CapitalUS

Questions

Who owns Ionlace?

Ionlace is currently owned by Heartcore Capital, through Heartcore Capital Fund IV, since 2023.

When did Heartcore Capital acquire Ionlace?

Heartcore Capital acquired Ionlace in 2023.

Look up another firm or company
Data refreshed weekly · Sourced from public filings · Report an issue